We have a diversified and balanced clinical development pipeline covering multiple therapeutic areas, including CNS, cardiovascular and immunological disorders, as well as orphan diseases.

Compound Mechanism of Action Target Indication Status Webcasts
         
Aprocitentan*  Dual endothelin receptor antagonist Resistant hypertension management Phase 3 Phase 3 initiation
Clazosentan** Endothelin receptor antagonist Vasospasm associated with aneurysmal subarachnoid hemorrhage (aSAH) Phase 3 Phase 3 advancing
Lucerastat Glucosylceramide synthase inhibitor Fabry disease Phase 3 Phase 3 initiation
ACT-541468 Dual orexin receptor antagonist Insomnia Phase 3 Phase 3 initiation
Cenerimod S1P1 receptor modulator Systemic lupus erythematosus Phase 2  
Selatogrel P2Y12 receptor antagonist Acute coronary syndrome (ACS) Phase 2  
ACT-774312 CRTH2 receptor antagonist Nasal polyposis Phase 2  
ACT-519276 GBA2/GCS inhibitor Orphan CNS diseases Phase 1  
ACT-539313 Selective orexin 1 receptor antagonist Anxiety Phase 1  
ACT-709478 T-type calcium channel blocker Epilepsy Phase 1  


* In collaboration with Janssen Biotech to jointly develop and solely commercialize aprocitentan worldwide
** Market registration trials are being conducted in Japan

"We are all encouraged to talk, share, communicate and participate."

Clinical Research Associate, Global Operations